Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00911261
Other study ID # EN3202-029
Secondary ID
Status Completed
Phase Phase 3
First received May 15, 2009
Last updated February 12, 2010
Start date August 2003
Est. completion date May 2005

Study information

Verified date February 2010
Source Endo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if Oxymorphone Extended Release is effective and safe in treating chronic pain in patients with cancer or neuropathic pain.


Description:

The purpose of this study is to evaluate the analgesic effectiveness and tolerability of oxymorphone ER in the treatment of cancer or neuropathic pain. Opioid-naïve subjects are gradually titrated from oxymorphone ER 5 mg, every 12 hours (q12h). All other subjects are titrated to a stable dose (defined as pain scores ≥ 4 on BPI Question 5 on 3 of 5 consecutive days while receiving the same total daily dose of study medication including rescue) with tolerable side effects. Subjects could potentially receive therapy for up to 12 months after the first dose of study medication.


Recruitment information / eligibility

Status Completed
Enrollment 223
Est. completion date May 2005
Est. primary completion date March 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years of age or older, with moderate to severe chronic malignant and/or neuropathic pain of at least 3 months duration and either:

1. have an initial pain intensity score of greater than 4 on a 10-point scale using BPI Question 5, if sub-optimally responding to their current analgesic regimen, or

2. have intolerable side effects to one or more components of their current opioid-containing analgesic regimen.

- Currently receive a stable (at least 2 weeks duration) analgesic regimen

- If female, must be practicing abstinence or using a medically acceptable form of contraception (e.g., intrauterine device, hormonal birth control, or double barrier method).

- Understand written and spoken English

- Have been informed of the nature of the study and provided written informed consent

Additional Inclusion Criteria for Cancer Patients Only:

- Have a life expectancy of at least 12 months

Additional Inclusion Criteria for Neuropathic Patients Only:

- Have a diagnosis of:

- post-herpetic neuralgia (PHN)

- diabetic neuropathy (DN)

- complex regional pain syndrome (CRPS)

- HIV neuropathy

- idiopathic sensory neuropathy

- traumatic peripheral neuropathy

- central neuropathic pain condition (spinal cord injury, post-stroke pain), OR

- other peripheral neuropathy (upon mutual agreement of the sponsor and investigator).

Exclusion Criteria:

- Have a positive pregnancy test (females only)

- Have a history of or active asthma or emphysema

- Have clinically significant hepatic impairment

- Have a history of alcohol or substance abuse within the last 3 years

- Have a history of opioid abuse within 6 months prior to study entry

- Have a known allergy or significant reaction to opioids, including codeine

- Have a known oxymorphone sensitivity or allergy

- Have received an investigational drug or product or participated in an investigational drug study within a period of 30 days prior to receiving study medication

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Oxymorphone Extended Release
Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets Treatment will consist of up to 12 months of dosing with Oxymorphone ER.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Endo Pharmaceuticals

Outcome

Type Measure Description Time frame Safety issue
Primary Tolerability Throughout the study Yes
Secondary Average daily pain intensity (Question 5 of BPI) Week 1-4, Month 12 No
Secondary Question 3, 4, 5, 6, 8, and 9 of BPI questionnaire Week 1-4, Month 12 No
Secondary Average daily dose of oxymorphone ER Daily No
Secondary Average daily dose of rescue medication Daily No
Secondary Total daily dose of oxymorphone ER and rescue medication Daily No
Secondary Time to stabilization Month 12 No
Secondary Patient/investigator global assessment of pain relief Month 12 No
Secondary Treatment Satisfaction Month 12 No
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients